Sign in
Stories
FDA Investigates CAR T Therapies
Share
4D Molecular Therapeutics Raises $300 Mi...
AB-2100 Phase 1/2 Trial Initiated
AGO Recognition Boosts BluePrint® Impact
Affini-T Therapeutics at J.P. Morgan Hea...
Allogene Therapeutics Restates Financial...
Cue Biopharma to Present Corporate Updat...
Overview
API
FDA investigates approved CAR T therapies for cancer risk, mandates long-term follow-up safety studies.
Ask a question
How might the FDA's investigation impact patient access to CAR T therapies?
What are the broader implications of the FDA's investigation for the development and regulation of CAR T therapies?
What measures can companies take to mitigate the risk of cancer in white blood cells associated with CAR T therapies?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Aug 2023
Sep 2023
Oct 2023
Coverage